Expression of the MAGE gene family in human hepatocellular carcinoma

Cancer

Volumn 85, Issue 6, 1999, Pages 1234-1240

  Tahara, Kouichirou ^a   Mori, Masaki ^a   Sadanaga, Noriaki ^a   Sakamoto, Yoshihiro ^b   Kitano, Seigo ^c   Makuuchi, Masatoshi ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c OITA UNIVERSITY   (Japan)

Author keywords

Hepatocellular carcinoma; Immunotherapy; MAGE gene family; MAGE 3 gene product; Tumor rejection antigen

Indexed keywords

ARTICLE; CLINICAL ARTICLE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MULTIGENE FAMILY; PRIORITY JOURNAL; PROTEIN DETERMINATION; RNA ANALYSIS;

AGED; ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 0033559628     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990315)85:6<1234::AID-CNCR4>3.0.CO;2-7     Document Type: Article

References (35)

1. De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994;40:360-9.
2. Gaugler B, van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994;179:921-30.
3. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
4. Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, van Pel A, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176:1453-7.
5. van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P, De Smet C, et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 1994;24:3038-43.
6. van der Bruggen P, Szikora JP, Boel P, Wildmann C, Somville M, Sensi M, et al. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. Eur J Immunol 1994;24:2134-40.
7. Tanaka F, Fujie T, Go H, Baba K, Mori M, Akiyoshi T. Efficient induction of antitumor cytotoxic T lymphocytes from a healthy donor using HLA-A2-restricted MAGE-3 peptide in vitro. Cancer Immunol Immunother 1997;44:21-6.
8. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995;63:883-5.
9. Sznol M, Zwierzina H. Immune monitoring of cancer vaccines. Ann Oncol 1996;7:667-70.
10. Inoue H, Mori M, Li J, Mimori K, Honda M, Nakashima H, et al. Human esophageal carcinomas frequently express the tumor-rejection antigens of MAGE genes. Int J Cancer 1995; 63:523-6.
11. Inoue H, Mori M, Honda M, Li J, Shibuta K, Mimori K, et al. The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma. Gastroenterology 1995;109: 1522-5.
12. Mori M, Inoue H, Mimori K, Shibuta K, Baba K, Nakashima H, et al. Expression of MAGE genes in human colorectal carcinoma. Ann Surg 1996;224:183-8.
13. Tanaka F, Mori M, Li J, Fujie T, Mimori K, Haraguchi M, et al. High frequency of the expression of the MAGE gene family in human esophageal carcinoma. Int J Oncol 1997; 10:1113-7.
14. Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res 1994;54:1766-71.
15. Mori M, Mimori K, Inoue H, Graham F. Barnard, Tsuji K, Nanbara S, et al. Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 1995;55:3417-20.
16. Thomas K, Elke ST, Fred G, Christoph S, Giulia C, Antonio J, et al. Identification and intracellular location of MAGE-3 gene product. Cancer Res 1995;55:2236-9.
17. Gunther FLH, Christoph S, Christoph N, Roland B, Jivko K, Frank ON, et al. MAGE-3 immunoreactivity in formalin-embedded primary and metastatic melanoma. Am J Pathol 1997;151:1549-53.
18. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 3rd edition [in Japanese]. Tokyo: Kanehara and Co., Ltd., 1992.
19. Eura M, Ogi K, Chikamatsu K, Lee KD, Nakano K, Masuyama K, et al. Expression of the MAGE gene family in human head-and-neck squamous-cell carcinomas. Int J Cancer 1995;64:304-8.
20. Russo V, Traversari C, Verrecchia A, Mottolese M, Natali P G, Bordignon C. Expression of the MAGE gene family in primary and metastatic human breast cancer: implications for tumor antigen-specific immunotherapy. Int J Cancer 1995; 64:216-21.
21. Yamashita N, Ishibashi H, Hayashida K, Kudo J, Takenaka K, Itoh K, et al. High frequency of the MAGE-1 gene expression in hepatocellular carcinoma. Hepatology 1996;24:1437-40.
22. Claude F, Fred G, Peter S, Christoph N, Christoph S, et al. High expression of MAGE-3 protein in squamous-cell lung carcinoma. Int J Cancer 1997;71:1119-21.
23. Tanaka F, Fujie T, Tahara K, Mori M, Takesako K, Sette A, et al. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A-24. Cancer Res 1997;57:4465-8.
24. Spies T, Bresnahan M, Bahram S, Arnold D, Blanck G, Mellins E, et al. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature 1990;348:744-7.
25. Brown MG, Driscoll J, Monaco JJ. Structural and serological similarity of MHC-linked LMP and proteasome (multicatalytic proteinase) complexes. Nature 1991;353:355-7.
26. Thor SP, Kirkin AF, Seremet T, Zeuthen J. Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines. Int J Cancer 1997;70:582-6.
27. Itoh K, Hayashi A, Nakao M, Hoshino T, Seki N, Shichijo S. Human tumor rejection antigens MAGE. J Biochem 1996; 119:385-90.
28. Toso JF, Oei C, Oshidari F, Tartaglia J, Paoletti E, Lyerly HK, et al. MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation. Cancer Res 1996;56:16-20.
29. Fleischhauer K, Fruci D, van Endert P, Herman J, Tanzarella S, Wallny HJ, et al. Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3. Int J Cancer 1996;68:622-8.
30. Dong R, Kimura A, Okubo R, Shinagawa H, Tamai H, Nishimura Y, et al. HLA-A and DPB1 loci confer susceptibility to Graves' disease. Hum Immunol 1992;35:165-72.
31. Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: HLA 1991: proceeding of the Eleventh International Histocompatibility Workshop and Conference. Tsuji K, Aizawa M, Sasazuki T, editors. Oxford: Oxford University Press, 1992:1605-8.
32. Paterson AC, Sciot R, Kew MC, Callea F, Dusheiko GM, et al. HLA expression in human hepatocellular carcinoma. Br J Cancer 1988;57:369-73.
33. Brasseur F, Rimoldi D, Lienard D, Lethe B, Carrel S, Arienti F, et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995;63: 375-80.
34. Patard JJ, Brasseur F, Gil Diez S, Radvanyi F, Marchand M, Francois P, et al. Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int J Cancer 1995;64: 60-4.
35. Katano M, Nakamura M, Morisaki T, Fujimoto K. Melanoma antigen-encoding gene-1 expression in invasive gastric carcinoma: correlation with stage of disease. J Surg Oncol 1997; 64:195-201.